lifted. However, silicone breast implants were restricted to women undergoing reconstructive surgery, and all patients were required to be followed in postmarketing surveillance protocols similar to our FDA 522 studies. Later that year, a $25-million judgment against Bristol-Myers Squibb was awarded for systemic symptoms. By the end of 1992, over 3000 lawsuits had been filed against Dow Corning. This number grew to more than 12,000 by the end of 1993, not reaching a peak until 1995 when more than 20,000 lawsuits had been filed. In May 1995, facing more than 20,000 individual lawsuits and 410,000 potential claims as part of the class action suite, Dow Corning filed for Chapter 11 bankruptcy effectively halting all litigation. Dow Corning ultimately offered $3.2 billion to settle tens of thousands of claims of injury from silicone breast implants as part of its bankruptcy reorganization plan. 3 
Enter the Medical Community Albeit a Bit Late
Between 1994 and 1999, more than 20 research articles were published concluding that although silicone breast implants may be responsible for localized problems, they did not cause any major systemic or autoimmune disorders including a large epidemiologic study from the Mayo Clinic, 4 the Harvard Nurses Epidemiologic Study published in the New England Journal of Medicine, 5 2 Scandinavian studies, 6, 7 and a 300-page independent report from the Institute of Medicine. 8 In 1996, given the complexity of the issues, 2 federal judges in New York, in an unprecedented move, appointed an impartial group of experts to review lawsuits establishing for the first time that evidence linking breast implant with systemic disease needed to be both unbiased and validated. That same year, the California Court of Appeal alone dismissed 1800 lawsuits against Dow Corning and Dow Chemical, the parent company. 2, 3 
Similar Struggles
So, at this point, should we all be depressed and go home? Definitely not! Today, breast implants are widely available and have never been safer. The techniques are more standardized; surgeons are better trained; patients are better informed; breast implant registries exist, and outcomes have been improved. I take away several important points from this history lesson. First, some patients were harmed and deserved to be compensated. Second, although passions were high, science ultimately trumped fear, and finally, the data after the FDA involvement were of markedly higher quality than that before the FDA became involved.
But were the observed problems solely due to the products, the technique, the surgeon? We all recall the ''hype cycle'' that Matt Barber described during his presidential address. It is clear that emotions related to mesh implants run just as high as they did with breast implants.
WTGGTTTGG
Dr Henry Thiede, a former AUGS president, was my chair for the first 2 years of my residency. Drs Thiede and Hilary Cholhan were instrumental in my decision to pursue urogynecology fellowship training. During Dr Thiede's retirement address at the University of Rochester, he presented this series of letters and offered $20 to whoever could guess what they stood for. As a poor resident at the time, I was thrilled to earn $20, and I will double that same offer today. Does anyone know what these letters stand for?
The correct answer, ''When the going gets tough, the tough gets going.'' Well, we did just that.
AUGS TAKES A STAND
Shortly after the 2011 FDA Safety Communication on the safety and effectiveness of transvaginally placed surgical mesh for pelvic organ prolapse, we became very concerned with the interferences between the patient and her physician that we were observing in various parts of the country. We observed a malpractice insurance company in New York City withdraw all coverage related to vaginally placed mesh even if a higher premium were paid. There was a request to ban the use of transvaginal mesh presented to the California Medical Society, who after consideration and with the AUGS representation denied that request, and as many know, Intermountain Healthcare in Utah banned the use of transvaginal mesh at all their facilities.
As you may recall from a year ago, my message upon accepting this presidency was about courage. The AUGS Board has had the courage to face the turmoil, the uncertainty, the information, and the misinformation regarding mesh for prolapse and mesh slings for stress incontinence. I hope you would agree that we showed courage when we published the AUGS Position Statement on the Restriction of Surgical Options for Pelvic Floor Disorders.
The AUGS Position Statement mentions several important points, but the fundamental message is that the decision of surgical alternatives should be made between the patient and her physician. Other important points were as follows:
& A complete restriction on the use of surgical mesh was not the stated intent of the FDA Safety Communication. & In fact, a ban on surgical mesh would prohibit the very surgical studies mandated by the FDA and recommended by the National Institutes of Health (NIH), the American College of Obstetrics and Gynecology, and the AUGS. & Any restriction of mesh slings for the treatment of stress urinary incontinence is clearly not supported by any professional organization, the literature, or the FDA.
The AUGS Board of Directors further recommended the adoption of the published AUGS credentialing guidelines for transvaginal mesh placement and for sacrocolpopexy. I would like to publicly thank Dr Cheryl Iglesia for her leadership and the other members of the AUGS Guidelines committee. We have certainly been keeping you busy.
We recommended the establishment of a broad group of trained pelvic floor reconstructive experts who, with the appropriate resources and patient management systems, would track both surgeons and procedures to identify and manage both mesh and nonYmesh-related complications. Yes, it is important to remember that non-mesh surgeries are also associated with complications, even some serious ones.
Finally, the Board recommended that a thorough, standardized informed consent process for mesh placement be universally adopted. We have made these materials publicly available through our Web site, www.augs.org.
Despite what some may have heard, there was no conspiracy that led Intermountain Healthcare to ban the use of transvaginal mesh for prolapse. Intermountain Healthcare had some legitimate local concerns. On behalf of the AUGS, I have personally communicated with the leaders at Intermountain Healthcare a number of times. I have found them to be incredibly open to discussing options to lift the ban with appropriate programs in place to ensure high-quality and standardized training, quality assurance, and management of complications.
Again, how could we as a community have done better? We should have, much earlier in the process, helped to determine who should be placing transvaginal mesh. Should someone who places mesh be required to have the requisite skills to identify, manage, and even remove mesh if necessary? Is placing mesh, but referring to all complications elsewhere, acceptable? I don't think so.
Quite frankly, we all bear some responsibility for the situation we find ourselves inVeither due to action or inaction. Perhaps, clinicians adopted new technology prematurely. Perhaps experienced clinician researchers were too resistant to consider new mesh options beyond native tissue repairs and therefore were not at the table to help design high-quality studies early enough.
The challenges of Intermountain Healthcare are not unique. In fact, it is quite the contrary. Our position statement and our credentialing guidelines on the use of transvaginal mesh and on sacrocolpopexy describe the need for adequate training, proctoring, surveillance, and monitoring of complications. However, most credentialing bodies do not have the resources to fully track such outcomes that may not occur intraoperatively, may in fact occur years after the procedure, and may occur without notification of the primary surgeon who even in good faith may not know that any complications have occurred. This is because either they do not have a comprehensive mechanism to collect these outcomes or because the patient has chosen to seek care elsewhere and is essentially lost to follow-up. We should all be cautious to assume that ''no news is good news.'' Theodore Roosevelt said, ''When you are asked if you can do a job, tell'em, 'Certainly I can!' Then get busy and find out how to do it.'' Immediately after the FDA issued the 522 orders mandating that companies perform prospective postmarketing surveillance studies to determine the safety and efficacy of transvaginal mesh, we have been actively working on building a multisponsor national registry, an item that had been on our strategic plan for years. It is arguably the largest undertaking this society had ever done. Has it been easy? Absolutely not! Have we been frustrated at time? Absolutely! However, when each of us considers the things in our lives that have truly mattered, I suspect few of those things were easy.
The Pelvic Floor Disorders Registry
The PFD Registry is an unprecedented, collaboration between the AUGS as the professional society, 4 industry participants, ACell, American Medical Systems, Boston Scientific and Coloplast, the FDA, the American College of Obstetrics and Gynecology, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, the NIH, and Quintiles Outcome, our registry vendor.
There are so many individuals and volunteers that I am unfortunately unable to thank each individually. I would like to thank Matt Barber for his tireless energy and vision; Cate Bradley, the chair; Emily Weber-LeBrun, the vice chair of the Registry Scientific Committee; and Vivian Sung, the chair of our Research Committee. They have participated in several conference calls each week and worked closely with the engaged clinical research teams at all 4 companies, Quintiles Outcome, the NIH, and the FDA. Finally, I would like to thank Kelly Lopez, our PFD Registry director, who manages to keep all the moving parts well greased and moving forward.
It is our hope that the PFD Registry is a step in the right direction and will provide a mechanism for surgeons to track their outcomes. For instance, credentialing bodies could mandate that physicians participate in the registry as a means of prospectively collecting their outcomes while providing meaningful benchmarking information to show surgeons whether they are within acceptable ranges of complications. It would more quickly demonstrate to those outliers that they need to invest in education or consider whether continuing to perform particular procedures is in the best interest of their patients. The option to refer may be in the best interest of the patient.
This has been another tumultuous year related to the controversy regarding the use of mesh in pelvic reconstructive surgery. Although this has primarily focused on the use of transvaginal mesh, it has included discussions regarding the benefits and complications associated with the use of abdominal mesh to repair pelvic organ prolapse and the use of mesh slings to treat stress incontinence. Sacrocolpopexy and slings are not immune. We need to become proactive and not reactive.
Our impossible voyage has taken us on several very long, treacherous, and winding roads. Over the last year, we held 2 face-to-face meetings with all the stakeholders to more efficiently reach consensus on overall design, data use, governance, and reporting structure. Each company with its team of clinical study designers, statisticians, and corporate attorneys has worked cooperatively with the AUGS to reach common ground and share a common native tissue control group, a major benefit of registry participation. Throughout the voyage, I have been impressed with the level of professionalism and cooperation shown not only when things went well but, in particular, when things didn't.
I roughly estimated more than 450 hours of conference calls since the FDA notification in January, 2011, each with between 6 and 20 participants. Despite what my partners and my family may think, I have not been on every single one of these conference calls.
The PFD Registry is essentially built, but it is undergoing extensive edit checking and refinement for it to be functional and validated at launch. Given our commitment to the FDA and the industry in regards to the 522 studies, we will be launching level 3 first, likely in the first quarter of 2014. Levels 1 and 2 will follow shortly.
Pursuing the PFD Registry is important not only for our society but for our field and most importantly for our patients. It is critical as we work to unravel ourselves from the mesh controversy, obtain high-quality evidence regarding the safety and efficacy of transvaginal mesh, and move this field forward in a new and bright direction. Having this infrastructure will be the key to preventing us from repeating our own past with mesh for sacrocolpopexy and even mesh slings for stress incontinence, the latter being the most highly studied procedure in urogynecology with high-quality level I evidence supporting both its safety and effectiveness.
The registry will provide a mechanism to evaluate new products as they become available and will allow us to become proactive. I believe that this registry will serve as a lasting model for postmarketing surveillance studies in the future.
Maine to California. However, it is important to note that, for many of us, it was the first computer-based examination we had ever taken, and the stress levels were very high. I'm pleased that 86% of us passed the examination.
Preparing for this examination was also associated with plenty of trepidation, worry, dread, and passion. The AUGS, in partnership with the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, created a comprehensive FPMRS review course led by Drs Mark Walters and Eric Jelovsek. Please join me in thanking them and the dedicated faculty for their efforts. We also created a question bank to help members review a wide range of related topics. Both the review course and the question bank closely followed the Learning Objectives published by the joint American Board of Obstetrics and Gynecology (ABOG)/American Board of Urology (ABU). However, it is important to understand that the AUGS and ABOG/ABU are completely independent organizations. As such, I appreciate Dee Fenner for presenting additional details regarding the examination and the process of board certification during the business meeting later today.
The AUGS remains committed to assisting those interested in becoming board certified. The next comprehensive review course will be held at the Omni Dallas on March 21 to 23, 2014. The Education Committee has been busy this year. Under the direction of Steve Swift, and with the involvement from AnnaMarie Connolly and Eric Jelovsek, the committee is overseeing an update and expansion of the question bank that will be available in February 2014 in plenty of time for those taking the next board examination.
Over the last century, it is interesting how the obstetrics and gynecology subspecialization has developed. In 1927, the ABOG was formed, and 6 years later, the American Board of Medical Specialties was launched. Approximately 40 years had passed before gynecologic oncology became a recognized subspecialty in 1972, with the subspecialties of reproductive endocrinology and infertility and maternal fetal medicine forming a year later.
The AUGS as a society was formed in 1979. Sadly, many of the individuals in the audience were not even born in 1979. I, however, have vivid memories of 1979. Saturday Night Fever was the top album on the chartsVyes, top album. We were still using vinyl albums at that time. My friends and I were very competitive with the game, Simon andI The Gynecologic Urology Society, which later became the American Urogynecologic Society, was formed.
About 25 years had passed before official accreditation of fellowship programs began in 1996, and almost 40 years had passed between the other 3 main subspecialties achieving board certification and FPMRS.
This journey was forged by the relentless pursuit of this goal by hard-working leaders in our field whose passion and determination we should all be very grateful. Having started my fellowship in 1997, at 1 of the first 4 accredited programs, at a time when board certification was anything but guaranteed, I am humbled to be standing before you, giving this address, the first year of board certification.
As we consider the names of the individuals that helped shape, drive, sustain, resuscitate, and launch this effort, we can appreciate the dynamic group and how their shared vision kept this effort alive and the important goal of raising and standardizing the training of specialists that care for women with PFDsVindividuals from gynecology such as Henry Thiede, Ray Lee, Linda Brubaker, Nicolette Horbach, Rick Bump, John DeLancey Norman Gant, Larry Gilstrap, and Dee Fenner and leading urologists such as Bill Steers, Schlomo Raz, Roger Dmochowski, Edward McGuire, and Stuart Howards. However, there were others, many more in fact. Please join me in thanking the many, many individuals whose hard work has resulted in the first new specialties in 40 years, female pelvic medicine and reconstructive pelvic surgery.
So what's next? Many of us are wondering, How passing the examination changes things for us? Does not passing change anything? We are unlikely to fully assess its impact for a number of years. It will take that long for the public, payers, peers, and patients to recognize female pelvic medicine and reconstructive surgery as they do other subspecialties in our field. I see board certification as raising the bar for our specialty. It is hard to argue that the collective knowledge in this field was not significantly improved through the examination preparation process.
GEARS KEEP TURNING
We are fortunate as an organization to be able to keep many projects moving forward efficiently. There are a few projects that I would like to highlight. These accomplishments would be impossible without a very important ingredientVyes, our volunteers. This last year, our society has witnessed an unprecedented amount of volunteer involvement. The number of people that have stepped up to get involved, the diversity of those individuals, and the number of hours they have selflessly contributed to the future of our society is nothing short of remarkable. I would like to thank our dedicated Board of Directors, committee chairs, and committee members for their many contributions.
Steve Swift, the chair of our Education Committee, oversaw the launch of an important resource this year, our new Fundamentals of Female Pelvic Surgery modules. I would also like to thank Vicki Handa, Marlene Corton, and Jerry Lowder who each chaired 1 of the 3 modules along with their working groups. These online case-based courses cover preoperative assessment (surgical management and anatomy) and (intraoperative complications and postoperative care). The AUGS Board felt so strongly that these would be of value and would serve as a foundation for education in our field that we made these 3 curricula free to members.
To promote and grow our online educational offerings and interactions with members, the AUGS Board created a new position within the Education CommitteeVthe AUGS Education Portal Director. Steve Minaglia was chosen among several strong applicants. I look forward to great things from him as we expand these offerings.
Public awareness for PFDs is growing, and more women than ever realize that they are not alone, that neither prolapse nor incontinence is a normal part of aging, and that safe and effective treatment options exist. However, many still do not realize these. This society has continued its effort to raise public awareness about PFDs.
Last November, we held 10 local ''Break Free from PFD'' events hosted by the AUGS members. This program has grown exponentially with 72 events registered, the majority occurring during Bladder Health Week this year, the week of November 12th.
Our patient education Web site, www.voicesforpfd.org, continued to expand this year. Our site had 73,285 unique visitors this year with over 200,000 page views.
Boston Scientific, Allergan, and Pfizer have generously supporting the PFD Alliance this year. We seek to expand sponsorship for the PFD Alliance to help us strengthen and expand the reach of our important and shared message.
We launched Overactive Bladder Central this year under the leadership of Peter Rosenblatt and Karen Noblett. OAB Central is a free resource for providers. Of the many useful tools on OAB central is a link to download the BladderTrakHer application. This application allows a patient to record a bladder diary and provides helpful behavioral therapy suggestions and reminders to improve bladder control. There is also a link to this application on the voicesforpfd.org Web site. As of September 19, 2013, we have had more than 877 downloads.
Our special interest groups (SIGs) are thriving. This year, we added a Global Health SIG that I think will be particularly interested in Dr Numann's lecture later today. I'm also pleased to report that the Allied Health involvement is growing remarkably. We have 99 members in the Allied Health SIG.
This year, we launched the AUGS Leadership Scholars program, the ''brain child'' of Deb Myers and the ''adopted child'' of Adam Steinberg. Over the last year, with mentoring from Sandy Culberston, Dee Fenner, John Gebhart, and Bob Shull, these capable and driven future leaders worked on practical and impactful projects that they presented to the AUGS Board this week. Take a close look; I'm expecting great things from these folks. Next year's group met earlier this week as well. Thank you to the participants and the faculty mentors.
As you can see, our society is in a major growth phase. Our membership committee, under the direction of Adam Steinberg, is constantly considering ways to add value for our members. Our membership grew this year from 1565 in 2012 to 1770 in 2013, representing a 13% increase. We have never been stronger or better positioned to make a significant impact in this field. With this realization, the AUGS Board decided to evaluate and update our image. The consultants we hired asked a wide variety of individuals for words to describe the AUGS, and as you can see, we are doing fairly well. As part of this effort, we felt it was time to update our look with a new logo. We've received very positive comments, and we hope you like the fresh new look.
The AUGS Staff Are Really a Remarkable Group of Dedicated Professionals
Without a doubt, they are the glue to the organization. Michelle Zinnert, the executive director, always reminds the Board to maintain a strategic focus. She is one of our greatest assets. Colleen Koski-Hughes keeps all the committees and daily operations working efficiently. Kelly Lopez skillfully runs the PFD Registry. Lauren, Tristan, Jamie, Mollie, and Alysa work each day to support the mission of the AUGS and to make our society the successful organization it is today. On behalf of the entire membership, thank you.
Moment of Silence
This year, we lost a number of valued members of our AUGS family. Ray Lee died this year. Ray had countless accomplishments and a personality that has been described as relentlessly hardworking, caring, and compassionate. Of note, he ''brokered a deal'' between the AUGS and the Society of Gynecologic Surgeons that ultimately convinced ABOG to explore whether our discipline was mature enough to warrant fellowship training. He also founded the Journal of Pelvic Surgery in 1995 that later became our journal in 2010, the Journal of Female Pelvic Medicine and Reconstructive Surgery. Under the excellent stewardship of Alf Bent and Linda Brubaker, our journal today is thriving with a growing number of subscriptions and submissions certainly benefiting from its recent indexing in Medline.
We also lost Robert Porges, MD, a New Yorker for most of his life; he served on the staff at the NYU Langone Medical Center for more than 50 years. He will be remembered as a wellrespected doctor to his patients and as a passionate teacher to his many students.
Finally, our society unexpectedly lost an energetic and caring research nurse, Robin Haff. Robin had worked with Vince Lucente for over a decade. That loss initially motivated Vince to help organize a major drive to increase donations to the AUGS PFD Research Foundation. It was incredible to see our members responding so generously. With support from American Medical Systems, we established the Robin Haff award to recognize a research staff member each year that has shown exemplary contributions in clinical research. I'm excited to announce that through combined contributions from American Medical Systems, Robin's father, Doug Woosnam, the AUGS Society, the AUGS PFD Research Foundation, and in particular, Vince Lucente, Miles Murphy, and Patrick Culligan, we were able to raise enough funds to endow this award, allowing it to continue in perpetuity.
I would like to take a moment of silence to recognize these individuals for their many contributions to the AUGS. Now, some exciting newsI The AUGS has collaborated with Evan Myers, Vivian Sung, Samantha Pulliam, and Cheryl Iglesia along with Missy Lavender from the Women's Health Foundation in preparing an exciting grant for submission to the Patient-Centered Outcomes Research Institute (PCORI) to develop evidence-based guidelines for the assessment of pelvic organ prolapse. The Patient-Centered Outcomes Research Institute is a congressionally funded but independent research group focused on supporting research to help patients make informed health care decisions. We have patients that deserve patient-centered outcomes that matter to them.
We have engaged members that care about clinical and quality outcomes. We have talented members who carry out the research that answers important clinical questions, and we have an existing evidence-based guidelines development process.
In this proposal, we take advantage of these strengths to demonstrate how the AUGS can serve as the key resource for meeting the needs of patients, clinicians, payers, and other stakeholders for the best possible evidence.
Through a very sophisticated systematic evidence review process, we will rigorously assess what we know about those outcomes, and based on that assessment, we will produce guidelines and quality measures where we have strong evidence and provide priorities for future research where we have weak or no evidence.
This proposal provides an opportunity for the AUGS to serve as a model for other specialty societies on how to respond to the challenges of the current health care environment. By developing sustainable ways to engage patients and members in a process that integrates guidelines, quality measures, and research needs, we can be a leader in helping to make our overall health care system more patient-centered, more evidence-based, and more affordable.
There will be opportunities for both fellows and faculty members to participate, through a competitive process that will be described in a request for applications to be released over the next week. There will also be an opportunity for the entire membership to provide input into the importance of specific outcomes. Stay tuned, this is very exciting for our society.
